tesamorelin ipamorelin mots c blend TESA/IPA/MOTS-C 16137828 aod mots c tesamorelin ipamorelin

CJC-1295 enhances the GHRH pathway, making the pituitary more responsive to natural GHRH signals and extending the duration of GH pulses

The mechanisms of action of Ipamorelin enable the peptide to stimulate production of secretions related to growth by the pituitary gland of animal studies

Most reactions are mild and manageable, but some may require medical attention

Safety, Monitoring, and Patient Selection Who Is the Ideal Candidate The ideal candidate for this therapy is an adult over the age of 30 experiencing the clinical signs of somatopausedecreased energy, poor sleep, increased visceral adiposity, and delayed recovery